11 results on '"Daccord, Magdalena"'
Search Results
2. World Heart Federation Cholesterol Roadmap 2022
- Author
-
Ray, Kausik K, Ference, Brian A, Séverin, Tania, Blom, Dirk, Nicholls, Stephen J, Shiba, Mariko H, Almahmeed, Wael, Alonso, Rodrigo, Daccord, Magdalena, Ezhov, Marat, Olmo, Rosa Fernández, Jankowski, Piotr, Lanas, Fernando, Mehta, Roopa, Puri, Raman, Wong, Nathan D, Wood, David, Zhao, Dong, Gidding, Samuel S, Virani, Salim S, Lloyd-Jones, Donald, Pinto, Fausto, Perel, Pablo, and Santos, Raul D
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Heart Disease ,Health Services ,Patient Safety ,Prevention ,Atherosclerosis ,Cardiovascular ,Clinical Research ,Heart Disease - Coronary Heart Disease ,Good Health and Well Being ,Humans ,Cholesterol ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Dyslipidemias ,Lipoproteins ,Apolipoproteins B ,Cardiovascular Diseases ,cholesterol ,low-density lipoprotein cholesterol prevention ,ASCVD ,lipid lowering therapy ,familial hypercholesterolaemia ,Cardiorespiratory Medicine and Haematology ,Cardiovascular medicine and haematology - Abstract
BackgroundAtherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-containing lipoproteins and the emergence of novel therapies provide new opportunities to better prevent ASCVD. The present update of the World Heart Federation Cholesterol Roadmap provides a conceptual framework for the development of national policies and health systems approaches, so that potential roadblocks to cholesterol management and thus ASCVD prevention can be overcome.MethodsThrough a review of published guidelines and research papers since 2017, and consultation with a committee composed of experts in clinical management of dyslipidaemias and health systems research in low-and-middle income countries (LMICs), this Roadmap identifies (1) key principles to effective ASCVD prevention (2) gaps in implementation of these interventions (knowledge-practice gaps); (3) health system roadblocks to treatment of elevated cholesterol in LMICs; and (4) potential strategies for overcoming these.ResultsReducing the future burden of ASCVD will require diverse approaches throughout the life-course. These include: a greater focus on primordial prevention; availability of affordable cholesterol testing; availability of universal cholesterol screening for inherited dyslipidaemias; risk stratification moving beyond 10-year risk to look at lifetime risk with adequate risk estimators; wider availability of affordable cholesterol-lowering therapies which should include statins as essential medications globally; use of adequate doses of potent statin regimens; and combination therapies with ezetimibe or other therapies in order to attain and maintain robust reductions in LDL-C in those at highest risk. Continuing efforts are needed on health literacy for both the public and healthcare providers, utilising multi-disciplinary teams in healthcare and applications that quantify both ASCVD risk and benefits of treatment as well as increased adherence to therapies.ConclusionsThe adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated to implement health policy, lifestyle changes and when needed pharmacotherapies earlier with investment in, and a shift in focus towards, early preventive strategies that preserve cardiovascular health rather than treat the consequences of ASCVD.
- Published
- 2022
3. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
- Author
-
Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe
- Published
- 2023
- Full Text
- View/download PDF
4. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
- Author
-
Rizzo, Manfredi, primary, Colletti, Alessandro, additional, Penson, Peter E., additional, Katsiki, Niki, additional, Mikhailidis, Dimitri P., additional, Toth, Peter P., additional, Gouni-Berthold, Ioanna, additional, Mancini, John, additional, Marais, David, additional, Moriarty, Patrick, additional, Ruscica, Massimiliano, additional, Sahebkar, Amirhossein, additional, Vinereanu, Dragos, additional, Cicero, Arrigo Francesco Giuseppe, additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bielecka-Dąbrowa, Agata, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Bytyçi, Ibadete, additional, Cafferata, Alberto, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Chlebus, Krzysztof, additional, Collet, Xavier, additional, Daccord, Magdalena, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, John Mancini, G.B., additional, David Marais, A., additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Mohammad Nabavi, Seyed, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Pirro, Matteo, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Serban, Maria-Corina, additional, Shehab, Abdullah M.A, additional, Shek, Aleksandr B., additional, Sirtori, Cesare R., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Wong, Nathan D., additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional
- Published
- 2023
- Full Text
- View/download PDF
5. The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration
- Author
-
Bedlington, Nicole, Abifadel, Marianne, Beger, Birgit, Bourbon, Mafalda, Bueno, Héctor, Ceska, Richard, Cillíková, Kristýna, Cimická, Zdenka, Daccord, Magdalena, Beaufort, Carine de, Dharmayat, Kanika I., Ference, Brian A., Freiberger, Tomáš, Geanta, Marius, Gidding, Samuel S., Grošelj, Urh, Halle, Martin, Johnson, Neil, Novakovic, Tanja, Májek, Ondrej, Pallidis, Athanasios, Peretti, Noel, Pinto, Fausto J., Ray, Kausik Kosh, Rees, Bleddyn, Reeve, John, Reiner, Željko, Santos, Raul D., Schunkert, Heribert, Šikonja, Jaka, Sokolovic, Milka, Tokgözoglu, Lale, Vrablík, Michal, Wiegman, Albert, and Gutiérrez-Ibarluzea, Iñaki
- Subjects
Declaration ,FH ,Doenças Cardio e Cérebro-vasculares ,children ,prevention ,cardiovascular disease ,EU best practice ,Cardiovascular Disease ,declaration ,implementation ,Children ,Cardiovascular Health ,Prevention ,CVD ,CVH ,EU ,Europe ,cardiovascular health ,familial hypercholesterolaemia ,health systems ,public health ,screening ,EU Best Practice ,ddc: 610 ,Implementation ,Screening ,Public Health ,Health Systems ,Familial Hypercholesterolaemia - Abstract
Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.
- Published
- 2022
6. Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations
- Author
-
Gidding, Samuel S, primary, Wiegman, Albert, additional, Groselj, Urh, additional, Freiberger, Tomas, additional, Peretti, Noel, additional, Dharmayat, Kanika I, additional, Daccord, Magdalena, additional, Bedlington, Nicola, additional, Sikonja, Jaka, additional, Ray, Kausik K, additional, Santos, Raul D, additional, Halle, Martin, additional, Tokgözoğlu, Lale, additional, Gutiérrez-Ibarluzea, Iñaki, additional, Pinto, Fausto J, additional, and Geanta, Marius, additional
- Published
- 2022
- Full Text
- View/download PDF
7. FindMyLipidClinic.com: A global Directory of lipid clinics and patient organisations to improve dyslipidemia care: FindMyLipidClinic.com
- Author
-
Stevens, Christophe A.T., additional, Lyons, Alexander R.M., additional, Dharmayat, Kanika I., additional, Brandts, Julia, additional, Vallejo-Vaz, Antonio J., additional, Daccord, Magdalena, additional, and Ray, Kausik K., additional
- Published
- 2022
- Full Text
- View/download PDF
8. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?
- Author
-
Catapano, Alberico L., primary, Daccord, Magdalena, additional, Damato, Elaine, additional, Humphries, Steve E., additional, Neely, R. Dermot G., additional, Nordestgaard, Børge G., additional, Pistollato, Michele, additional, and Steinhagen-Thiessen, Elisabeth, additional
- Published
- 2022
- Full Text
- View/download PDF
9. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?
- Author
-
Catapano, Alberico L, Daccord, Magdalena, Damato, Elaine, Humphries, Steve E, Neely, R. Dermot G., Nordestgaard, Børge G., Pistollato, Michele, Steinhagen-Thiessen, Elisabeth, Catapano, Alberico L, Daccord, Magdalena, Damato, Elaine, Humphries, Steve E, Neely, R. Dermot G., Nordestgaard, Børge G., Pistollato, Michele, and Steinhagen-Thiessen, Elisabeth
- Abstract
Background and aims: Elevated concentrations of Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This study aims to investigate the clinical utility for patients, and the economic benefit to healthcare systems and society of measuring Lp(a) concentrations more widely today. Methods: We conducted a structured literature review to identify the economic and health benefits and costs of measuring the Lp(a) concentration, potential barriers hindering the uptake of the measure, and potential solutions to address them. These findings were then discussed in an advisory board attended by experts and patient organisations. Results: It was found that if Lp(a) concentration is measured more widely today, patients, healthcare system and society would experience clinical and economic benefits even before specific Lp(a) lowering pharmacological treatments become available. Furthermore, a wider uptake of the Lp(a) measurement would support the development of epidemiological data. Conclusions: For Lp(a) measurement to be more widely used, key barriers which are hindering its uptake need to be addressed. These include i) the perception that the measure may have limited clinical value, ii) lack of awareness on Lp(a), iii) lack of data on the CV benefit of reducing Lp(a), iv) technical and clinical guidelines barriers, and v) healthcare system barriers. Scientific communities and industry should collaborate to address technical challenges and deficiencies in clinical guidelines. However, policy intervention will be crucial for national ASCVD plans to acknowledge the importance of Lp(a).
- Published
- 2022
10. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
- Author
-
Banach, Maciej, primary, Penson, Peter E., additional, Fras, Zlatko, additional, Vrablik, Michal, additional, Pella, Daniel, additional, Reiner, Željko, additional, Nabavi, Seyed Mohammad, additional, Sahebkar, Amirhossein, additional, Kayikcioglu, Meral, additional, and Daccord, Magdalena, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel(ILEP)
- Author
-
Penson, Peter E., Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P., Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P., Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung‐I, Mancini, G.B. John, Haehling, Stephan, Banach, Maciej, Acosta, Julio, Al‐Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Bhaskar, Sonu, Bytyçi, Ibadete, Bjelakovic, Bojko, Bruckert, Eric, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, Mancini, G.B. John, Marais, A. David, Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Nabavi, Seyed Mohammad, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Sattar, Naveed, Serban, Maria‐Corina, Shehab, Abdullah M.A., Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung‐I, Zhisheng, Jiang, and Zirlik, Andreas
- Abstract
Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)—what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real‐world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step‐by‐step patient‐centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long‐term compliance with lipid‐lowering therapy.
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.